This site is intended only for healthcare professionals residing in Malaysia

Search

Menu

Close

Log Out Our medicinesTherapy AreaExplore contentExplore contentEventsDownloadable materialsVideosLet’s connectLet's ConnectContact usPfizer medical information
Home

Menu

Close

RTIs & Acute Otitis MediaUpper Respiratory Tract Infections (Upper RTIs)Acute Bacterial SinusitisPharyngitis/TonsillitisAcute Otitis MediaAcute Otitis MediaLower Respiratory Tract Infections (Lower RTIs)Community-Acquired PneumoniaAcute Bacterial Exacerbation of Chronic BronchitisSTIsSexually Transmitted Infections (STIs)Infections by Chlamydia trachomatisInfections by Neisseria gonorrhoeaeChancroid/Genital Ulcers MenSSTIsSkin and Soft-Tissue Infections (SSTIs)Uncomplicated Skin and Soft-Tissue InfectionsSafetySafetySafetyAdditional InformationAdditional InformationIndication and SusceptibilityFormulationsMode of ActionReconstitution of Powder for Oral Suspension for PediatricsPediatric AdministrationResourcesResourcesPrescribing InformationEventsMaterialsVideos

Additional Information  |  Mode of Action

Mode of Action

Effective treatment from a range of once-daily formulations1

Resources Watch the ZITHROMAX® Mode of Action Video Watch now LoadingZITHROMAX Mode of Action
  • ZITHROMAX is an azalide, a sub-class of the macrolide antibiotics1,2; it is chemically different2-4 and has a substantially longer half-life compared with other macrolide antibiotics3–7
  • ZITHROMAX is the only once-daily antibiotic in this class1,4-6
  • ZITHROMAX inhibits protein synthesis at ribosomes within susceptible bacterial cells1
  • ZITHROMAX concentrations are markedly higher in tissues than in plasma – up to 50 times the maximum observed concentration in plasma2
  • Concentrations in target tissues, such as lung, tonsil, and prostate, exceed the MIC90 for likely pathogens after a single dose of 500 mg2
  • Macrophages and polymorphonuclear leucocytes concentrate ZITHROMAX at levels greater than those found in tissues,7 delivering high concentrations at the site of infection; phagocytosis then enables release of ZITHROMAX in high concentrations2
  • Once-daily regimens help optimize patient adherence to antibiotic treatment in outpatient/ambulatory settings8

The most recent local resistance data available must always take precedence when selecting antimicrobial therapy; in settings where local resistance data are not available, national and international guidelines can help inform antimicrobial choice.
As with erythromycin and other macrolides, rare serious allergic  reactions, including angioedema and anaphylaxis (rarely fatal), Dermatologic reactions including Acute Generalized Exanthematous Pustulosis (AGEP), Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN) (rarely fatal), and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have been reported. Some of these reactions with azithromycin have resulted in recurrent symptoms and required a longer period of observation and treatment. If an allergic reaction occurs, the drug should be discontinued and appropriate therapy should be instituted. Physicians should be aware that reappearance of the allergic symptoms may occur when symptomatic therapy is discontinued1

You might also be interested in...Resources Pediatrics: How to Properly Administer ZITHROMAX® Watch now LoadingReferences:Pfizer Malaysia ZITHROMAX Prescribing Information. Available at: https://labeling.pfizer.com/ShowLabeling.aspx?id=17705. Accessed January 2024.Data on file, Pfizer. Azithromycin Core Data Sheet Version 14.0, April 2016.Drew RH, et al. Pharmacotherapy. 1992;12(3):161–73.Amsden GW. Clin Ther. 1996;18(1):56–72.Erythrocin 500 Tablets Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/
product/404/smpc. Accessed June 2023.Clarithromycin 250 mg Film-coated Tablets Summary of Product Characteristics. Available at: https://
www.medicines.org.uk/emc/product/4358/smpc. Accessed June 2023.Lode H. Eur J Clin Microbiol Infect Dis. 1991;10(10):807–12.Kardas P. J Antim Chem. 2007;59:531–6.Additional Information ZITHROMAX® Safety Information Find out more Loading
PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign inRegisterAccountSign Out

This site is intended only for healthcare professionals residing in Malaysia. If you are a member of public wishing to access information on a specific medicine, please consult with your doctor.

 

This website is brought to you by
Pfizer (Malaysia) Sdn Bhd 197801003134
(40131-T)
Level 10 & 11, Wisma Averis (Tower 2),
Bangsar South, No. 8, Jalan Kerinchi, 
59200 Kuala Lumpur, Malaysia.
Tel: 603-2281 6000 
Fax: 603-2281 6388 
 

Copyright © 2023 Pfizer Limited. All rights reserved.

 

PP-ZIT-MYS-0243-28FEB2024
You are now leaving the PfizerPro Malaysia website
​
You are now being directed to a third-party website. It is clarified that Pfizer will not be collecting, storing, or accessing any personal information shared by you on the third-party website and Pfizer's Privacy Policy will not apply. Pfizer does not review or control or endorse the content of the third-party website and shall have no liability / assumes no responsibility for any issues arising out of you accessing the third-party website, accuracy of the information, practices, and standards of the third-party website. You will be bound by the Privacy Policy and Terms of Use of the third-party website and be solely responsible for your interactions with that website.
 
     PP-UNP-MYS-0077 - 10FEB2023